---
title: 'aSynPEP-DB: a database of biogenic peptides for inhibiting α-synuclein aggregation'
date: '2023-11-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38011719/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231128170723&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Parkinson's disease (PD) is the second most prevalent neurodegenerative
  disorder, yet effective treatments able to stop or delay disease progression remain
  elusive. The aggregation of a presynaptic protein, α-synuclein (aSyn), is the primary
  neurological hallmark of PD and, thus, a promising target for therapeutic intervention.
  However, the lack of consensus on the molecular properties required to specifically
  bind the toxic species formed during aSyn aggregation has hindered the development
  ...
disable_comments: true
---
Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, yet effective treatments able to stop or delay disease progression remain elusive. The aggregation of a presynaptic protein, α-synuclein (aSyn), is the primary neurological hallmark of PD and, thus, a promising target for therapeutic intervention. However, the lack of consensus on the molecular properties required to specifically bind the toxic species formed during aSyn aggregation has hindered the development ...